巨细胞病毒血症与撒哈拉以南非洲HIV儿童启动抗逆转录病毒治疗后的死亡率相关
该研究基于ARROW试验的498名HIV儿童,采用病例队列设计,在启动以非核苷类逆转录酶抑制剂为基础的抗逆转录病毒治疗时、治疗后12周和84周定量CMV。结果显示基线CMV血症与死亡率独立相关,津巴布韦和乌干达的关联强度不同,但均显著。
要点
- HIV儿童启动ART时基线CMV血症与死亡率独立相关。
- 津巴布韦队列中CMV载量每升高1 log10,死亡风险增加2.74倍。
- 乌干达队列中可检测CMV血症者死亡风险为不可检测者的3.15倍。
核心结论
- 在撒哈拉以南非洲启动ART的HIV儿童中,CMV血症与死亡率独立相关。
研究设计与样本
- 采用病例队列设计,纳入ARROW试验中498名儿童(中位年龄6.3岁,IQR 2.3-9.6),来自乌干达336名和津巴布韦162名。
- 在启动非核苷类逆转录酶抑制剂为基础的ART时、治疗后12周和84周,用实时聚合酶链反应定量CMV。
- 使用多变量模型评估基线CMV血症与死亡率的关联,调整基线HIV RNA、CD4+百分比和IL-6浓度。
主要发现
- 津巴布韦(检测限20 copies/mL)119/162(73%)儿童可检测到CMV,CMV载量每升高1 log10与死亡风险增加相关(aHR=2.74;95%CI 1.57-4.77)。
- 乌干达(检测限120 copies/mL)89/336(26%)儿童可检测到CMV血症,与不可检测者相比死亡风险增加3倍(aHR=3.15;95%CI 1.11-8.93)。
- 在48名有免疫表型数据的儿童亚组中,未发现CMV与免疫激活相关的证据。
临床怎么用
- 对启动ART的HIV儿童应考虑CMV血症的筛查和监测,尤其在高CMV检出率地区。
- CMV载量可辅助识别死亡高风险HIV儿童,但需进一步研究是否通过抑制CMV血症降低死亡率。
局限性
- 研究为观察性设计,不能确定CMV血症与死亡的因果关系。
- 两个国家使用的CMV检测方法检测限不同(20 vs 120 copies/mL),可能影响结果比较。
- 免疫表型分析仅基于48名儿童的亚组,统计效力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cytomegalovirus (CMV) co-infection is associated with mortality in adults with human immunodeficiency virus (HIV) infection, but whether CMV is associated with mortality in children with HIV remains uncertain. METHODS: In 498 children (median age 6.3 years, interquartile range 2.3-9.6) enrolled in the ARROW trial (ISRCTN24791884) in Uganda (336/498) and Zimbabwe (162/498) selected using a case-cohort design, CMV was quantified using real-time polymerase chain reaction at initiation of non-nucleotide reverse transcriptase inhibitor-based antiretroviral therapy (ART), 12 weeks post-ART, and 84 weeks post-ART. Associations between baseline CMV viremia and mortality were evaluated using multivariable models, adjusting for baseline HIV RNA, CD4+ percentage, and IL-6 concentrations. RESULTS: Baseline CMV viremia was associated with mortality, with relationships differing by country and assay. In Zimbabwe (assay limit of detection 20 copies/mL), 119/162 (73%) children had detectable CMV, and each log10 higher CMV viral load was associated with over 2-fold higher mortality (adjusted hazard ratio [aHR] = 2.74; 95% CI 1.57-4.77). In Uganda (assay limit of detection 120 copies/mL), 89/336 (26%) children had detectable CMV viremia, which was associated with 3-fold higher mortality compared to undetectable CMV (aHR = 3.15; 95% CI 1.11-8.93). In a subset of 48 children with immunophenotyping data, we found no evidence that CMV was associated with immune activation. CONCLUSIONS: Cytomegalovirus viremia is independently associated with mortality in children with HIV starting ART in sub-Saharan Africa. Future studies should define the underlying mechanisms and evaluate whether suppressing CMV viremia reduces mortality in children with HIV.
引用
- Fisayo T, Evans C, Mutasa K, et al. Cytomegalovirus Viremia Is Associated With Mortality Among Children With HIV Starting Antiretroviral Therapy in Sub-Saharan Africa. Clin Infect Dis. 2026. PMID: 42262841. doi:10.1093/cid/ciag354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。